Remove Events Remove Patients Remove Physicians Remove Safety
article thumbnail

MHRA warns of serious eye-related adverse events after Dupixent use

Pharmaceutical Technology

GlobalData anticipates that this safety update will likely raise physician and regulator vigilance regarding long-term Dupixent use but is unlikely to impact overall prescribing patterns for the product. This will, however, likely trigger Dupixent’s competitors to look more closely at the safety of their products.

article thumbnail

Revolutionizing Pharmacovigilance with Proactive Signal Detection

PM360

Up to now, drug safety teams have relied primarily on reactive reporting systems for pharmacovigilance (PV) or real-world drug safety monitoring. Most traditional signal detection methods focus on disproportionality, meanwhile calling attention to higher-than-expected correlations between the suspect drug and an adverse event (AE).

Safety 106
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

ESMO 2022: Ten key takeaways on Europe’s top oncology event

Clarivate

Clarivate oncology experts share key takeaways from the 2022 ESMO Congress and their expected impact on the drug treatment landscape and patients. Positive outcomes in a key patient segment could broaden TRODELVY’s uptake in metastatic breast cancer. Market impact.

article thumbnail

10 Ways to Attract New Patients from Key Local Employers

Healthcare Success

Help Providers Win New Patients from Large Local Businesses with These Tactics. Large or dominant employers in your local communities are excellent targets of opportunity for new patients and cases. This mutually beneficial partnership helps businesses create a healthier workforce and increases brand trust and patient volume.

Patients 101
article thumbnail

Using data analytics to better manage care transitions

Clarify Health

Care transitions are often critical periods where patients may be vulnerable to complications or relapses. Ensuring effective management of care transitions is not just a matter of patient convenience; it is pivotal to enhancing patient outcomes, improving population health, and reducing unnecessary medical spend.

article thumbnail

AbbVie’s Skyrizi® shows long-term efficacy in psoriatic arthritis

European Pharmaceutical Review

Long-term data from the KEEPsAKE trials shows more than half of adult psoriatic arthritis patients receiving Skyrizi ® (risankizumab, 150mg) achieving a 90 percent reduction in the Psoriasis Area and Severity Index (PASI 90) and an American College of Rheumatology 20 (ACR20) response at 100 weeks. The two studies are ongoing. .

Safety 66
article thumbnail

AstraZeneca BTK inhibitor tablet approved in EU for leukaemia

European Pharmaceutical Review

Today’s approval offers physicians and patients in the EU more flexibility to determine the right treatment plan and enables more patients to potentially benefit from this medicine,” explained Dave Fredrickson, Executive Vice President of AstraZeneca’s Oncology Business Unit.

Safety 80